Battling colorectal cancer via s-triazine-based MMP-10/13 inhibitors armed with electrophilic warheads for concomitant ferroptosis induction; the first-in-class dual-acting agents

Morcos, Christine A.; Khattab, Sherine N.; Haiba, Nesreen S.; Bassily, Rafik W.; Abu-Serie, Marwa M.; Teleb, Mohamed

doi:10.1016/j.bioorg.2023.106839

Bioorganic Chemistry

2023

DOI: 10.1016/j.bioorg.2023.106839

|View full text |Cite

Battling colorectal cancer via s-triazine-based MMP-10/13 inhibitors armed with electrophilic warheads for concomitant ferroptosis induction; the first-in-class dual-acting agents

Christine A. Morcos,

Sherine N. Khattab,

Nesreen S. Haiba

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors

Khalil,

El-Sheshtawy,

Khattab

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors

Khalil,

El-Sheshtawy,

Khattab

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer

Shi,

Chen,

2024

J. Med. Chem.

View full text Add to dashboard Cite

Ferroptosis is a type of iron-dependent programmed cell death characterized by the dysregulation of iron metabolism and the accumulation of lipid peroxides. This nonapoptotic mode of cell death is implicated in various physiological and pathological processes. Recent findings have underscored its potential as an innovative strategy for cancer treatment, particularly against recalcitrant malignancies that are resistant to conventional therapies. This article focuses on ferroptosis-based therapeutic strategies for precision cancer treatment, covering the molecular mechanisms of ferroptosis, four major types of ferroptosis inducers and their inhibitory effects on diverse carcinomas, the detection of ferroptosis by fluorescent probes, and their implementation in image-guided therapy. These state-of-the-art tactics have manifested enhanced selectivity and efficacy against malignant carcinomas. Given that the administration of ferroptosis in cancer therapy is still at a burgeoning stage, some major challenges and future perspectives are discussed for the clinical translation of ferroptosis into precision cancer treatment. ■ SIGNIFICANCE • The potential of ferroptosis as an innovative strategy for precision cancer therapy is highlighted. • Recent advances are discussed from three perspectives: molecular mechanism and regulation, anti-cancer ferroptosis inducers, and ferroptosis probes for image-guided therapy. • The strengths and weaknesses of ferroptosis modulators and probes are analyzed in terms of current progress and technical barriers. • Future perspectives are emphasized to advance ferroptosis-based therapies toward clinical use for cancer treatment.

show abstract

Non-small cell lung cancer sensitisation to platinum chemotherapy via new thiazole-triazole hybrids acting as dual T-type CCB/MMP-9 inhibitors

Gamal,

Ismail,

Omar

et al. 2024

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Battling colorectal cancer via s-triazine-based MMP-10/13 inhibitors armed with electrophilic warheads for concomitant ferroptosis induction; the first-in-class dual-acting agents

Cited by 4 publications

References 82 publications

Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors

Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors

Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer

Non-small cell lung cancer sensitisation to platinum chemotherapy via new thiazole-triazole hybrids acting as dual T-type CCB/MMP-9 inhibitors

Contact Info

Product

Resources

About